Patrys’ PAT-DX1 Hijacks a Nucleoside Transporter to Cross Cell Membranes

Patrys is a publicly-listed company company focused on developing novel antibody technologies for cancer and NETosis-driven inflammatory diseases

Get news and updates from Patrys delivered to your inbox.

Keep up to date with the latest news from Patrys by following us on social media.

Menu